Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
The highest dose of Lilly's amylin-Zepbound combo yielded average weight loss of 54.1-pounds at 48 weeks, with A1C-lowering benefits shown, too.
Marissa Russo
Sep 30, 2026 1:52pm
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Sep 30, 2026 4:57am
Lilly sets up next-gen obesity war with phase 3 retatrutide data
Sep 30, 2026 3:06am
Novo agrees $2.6B deal for Hengrui's preclinical GLP-1/GIP drug
Sep 29, 2026 3:50am
Roche drops obesity antibody after flunked interim analysis
Sep 28, 2026 11:03am
Fierce Pharma
Novo struggles to appease restless investors with new strategy
Sep 21, 2026 10:50am
